ĀÜĄņĀŅĀ×

Dr. Lipp is currently the Senior Vice President of Pharmaceutical Development at Nocion Therapeutics Inc., a biotech startup focusing on the development of novel drug candidates (ā€œNocionsā€) for the treatment of various conditions related to pain and itch. He has over two decades of experience in pharmaceutical development and drug delivery technologies ranging from the preclinical stage through commercial approval. Prior to joining Nocion, Dr. Lipp was head of Pharmaceutical Development at Civitas Therapeutics through its acquisition by Acorda Therapeutics. At Acorda, Dr. Lipp was Site Head of the Acorda Waltham R&D Facility and led the efforts related to the Chemistry, Manufacturing, and Control (CMC) activities associated with Inbrijaā„¢ which was approved by the FDA in 2018 as the first-in-class treatment for OFF episodes in Parkinsonā€™s Disease.

Dr. Lipp was previously the Vice President of Pharmaceutical Development and Intellectual Property at PULMATRiX where he was a co-inventor of the iSPERSEā„¢ technology. Prior to PULMATRiX, Dr. Lipp was Director of Formulation Development at Alkermes, managing and directing formulation and pharmaceutical development activities related to pulmonary, injectable, and oral platforms. Dr. Lipp began his career as a Post-Doctoral Fellow working with Advanced Inhalation Research (AIRĀ®), where he became a Staff Scientist focusing on pulmonary product development prior to its acquisition by Alkermes.